Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension

Journal of Hepatology

Volumn 32, Issue 1, 2000, Pages 25-31

  Pulgar, Sofía Pérez Del ^a   Pizcueta, Pilar ^a,b   Engel, Pablo ^c   Bosch, Jaume ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Pilar Pizcueta   (Spain)

^c NONE

Author keywords

Adhesion molecules; CD11b CD18; Cirrhosis; Hepatotoxicity; Inflammation; Portal hypertension; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD11B ANTIGEN; CD18 ANTIGEN; ENDOTOXIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INFLAMMATION; LIVER CIRRHOSIS; LIVER TOXICITY; MALE; MONOCYTE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; SEPTIC SHOCK;

EID: 0343314896     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80185-3     Document Type: Article

References (36)

1. Morrison DC, Ryan JL. Endotoxins and disease mechanisms. Annu Rev Med. 38:1987;417-432.
2. McCabe WR. Serum complement levels in bacteremias due to gram-negative organisms. N Engl J Med. 288:1973;21-23.
3. Brandtzaeg P. Significance and pathogenesis of septic shock. Curr Top Microbiol Immunol. 216:1996;15-37.
4. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by human recombinant cachectin. Science. 234:1986;470-474.
5. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 9:1993;317-343.
6. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 103:1993;565-575.
7. Van der Poll T, Bueller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med. 322:1990;1622-1627.
8. Genecin P, Groszmann RJ. Portal hypertension. Schiff E, Schiff L. Diseases the Liver, 7th ed. 1993;935-973 Lippincot, Philadelphia.
9. Bosch J, Pizcueta P, Feu F, Fernández M, García-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am. 21:1992;1-14.
10. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in a portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 244:1983;G52-G57.
11. Gimbrone MA Jr., Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest. 99:1997;1809-1813.
12. Topper JN, Cai J, Falb D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively upregulated by steady laminar shear stress. Proc Natl Acad Sci USA. 93:1996;10417-10422.
13. Hecker M, Mulsch A, Bassenge E, Busse R. Vasoconstriction and increased flow: two principal mechanims of shear stress-dependent endothelial autacoid release. Am J Physiol. 265:1993;H828-H833.
14. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE, Groszmann RS. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology. 111:1996;1627-1632.
15. Fernández M, García-Pagán JC, Casadevall M, Mourelle MI, Piqué JM, Bosch J, et al. Acute and chronic cycloxigenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology. 110:1996;1529-1535.
16. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJR, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology. 103:1992;1909-1915.
17. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology. 103:1992;235-239.
18. Jaeschke H. Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases. Am J Physiol. 1997;G602-G611.
19. Pizcueta P, Casamitjana R, Bosch J, Rodés J. Decreased systemic vascular sensitivity to norepinnephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol. 258:1990;G191-G195.
20. Devière J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, et al. Excessive in vitro bacterial lipopolysaccharideinduced production on monokines in cirrhosis. Hepatology. 11:1990;628-634.
21. Panés J, Perry MA, Anderson DC, Muzykantov VR, Carden DL, Miyasaka M, et al. Portal hypertension enhances endotoxin-induced intercellular adhesion molecule 1 up-regulation in the rat. Gastroenterology. 100:1996;866-874.
22. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology. 108:1995;761-767.
23. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol. 66:1997;101-195.
24. Fong Y, Marano MA, Moldawer LL, Calvano SE, Kenny JS, Allison AC, et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest. 85:1990;1896-1904.
25. Hamilton TA, Adams DO. Molecular mechanims of signal transduction in macrophages. Immunol Today. 8:1987;151-158.
26. Gimbrone MA Jr. Vascular endothelium in health and disease. Haber E. Molecular Cardiovascular Medicine. 1995;49-61 Scientific American Medicine.
27. Pober JS, Cotran. Cytokines and endothelial cell biology. Physiol Rev. 70:1990;427-451.
28. Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 6:1992;2591-2599.
29. Wang S, Yan L, Wesley RA, Danner RL. Nitric oxide increases tumor necrosis factor production in differentiated U937 cells by decreasing cyclic AMP. J Biol Chem. 272:1997;5959-5965.
30. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
31. Santucci L, Fiorucci S, Chiorean M, Brunori PM, Di Mateo FM, Sidoni A, et al. Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. Gastroenterology. 111:1996;736-744.
32. Matuschtak GM, Mattingly ME, Tredway TL, Lechner AJ. Liver-lung interactions during E. coli endotoxemia. TNF-alpha:-leukotriene axis. Am J Respir Crit Care Med. 149:1994;41-49.
33. Soupison T, Yang S, Bernard C, Moreau R, Kirstetter P, D'Almeida M, et al. Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. Clin Sci. 91:1996;29-33.
34. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor a, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 23:1996;1616-1621.
35. Chu CJ, Lee FY, Wang S, Lu RH, Tsai YT, Lin HC, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci. 93:1997;219-225.
36. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol. 276:1999;G687-G693.